Retrophin Provides Corporate Update and 2020 Outlook

    NEXT STORY
    KaNDy Therapeutics Announces Positive Phase 2b Data in Post-Menopausal Women with its Lead Non-Hormonal Product NT-814
    PREV STORY
    Emergent BioSolutions Receives EMA Agreement for Proposed Development Path of Investigational Chikungunya VLP Vaccine Candidate
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    Exalenz Announces Fourth Quarter and Full Year 2017 Financial Results

    - 2017 revenue increased 127% to $9.5 million, compared with $4.2 million in 2016 ...

    author_avatar
    NASDAQ Market News

    EyePoint Pharmaceuticals Announces YUTIQ® Presentations at the American Academy of Ophthalmology 2019 Annual Meeting

    author_avatar
    NASDAQ Market News

    Adverum Biotechnologies Reports First Quarter 2018 Financial Results and Provides Corporate Update

    MENLO PARK, Calif., May 09, 2018 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq:ADVM), a ...

    author_avatar
    NASDAQ Market News